Association of human papillomavirus type 16 E7 and HLA class I antigen expression in cervical premalignant and malignant lesions

International Journal of Biological Markers

Volumn 22, Issue 2, 2007, Pages 124-131

  Wang, J F ^a   Wang, Chuan Xin ^a   Wang, L S ^a   Zhang, J ^a   Yang, X J ^a   Liu, M ^a   Zheng, G X ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cervix neoplasm; HLA antigen; HPV16 E7; actin

Indexed keywords

BETA ACTIN; HLA ANTIGEN CLASS 1; PROTEIN E7;

ADULT; AGED; ARTICLE; CORRELATION COEFFICIENT; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRECANCER; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LOAD;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 34447335827     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3992     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Zanotti KM, Belinson J. Update on the diagnosis and treatment of human papillomavirus infection. Cleve Clin J Med 2002; 69: 948-61.
3. McCree DH, Leichliter JS, Hogben M, et al. National survey by specialty of U. S. physicians' HPV screening practices. Prev Med 2003; 36: 159-63.
4. Mammas IN, Zafiropoulos A, Sifakis S, et al. Human papillomavirus (HPV) typing in relation to ras oncogene mRNA expression in HPV-associated human squamous cervical neoplasia. Int J Biol Markers 2005; 20: 257-63.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
6. Herber R, Liem A, Pitot H, et al. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996;70: 1873-81.
7. Scheffner M, Munger K, Byrne JC, et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88: 5523-7.
8. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89: 213-28.
9. Kozuka T, Aoki Y, Nakagawa K, et al. Enhancer-promoter activity of human papillomavirus type 16 long control regions isolated from cell lines SiHa and CaSki and cervical cancer biopsies. Jpn J Cancer Res 2000; 91: 271-9.
10. Evans EM, Man S, Evans AS, et al. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57: 2943-50.
11. De Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998; 58: 724-31.
12. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004; 4: 675-87.
13. Alani RM, Munger K. Human papillomaviruses and associated malignancies. J Clin Oncol 1998; 16: 330-7.
14. Marchetti I, Zavaglia K, Bertacca G, et al. HPV testing and Pap test: role for a combined approach in a non-screened population. Int J Biol Markers 2006; 21: 149-56.
15. Lo KW, Wong YF, Chan MK, et al. Prevalence of human papillomavirus in cervical cancer: a multi-center study in China. Int J Cancer 2002; 100: 327-31.
16. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2194-8.
17. Terry G, Ho L, Jenkins D, et al. Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction technique. Arch Virol 1993; 128: 123-33.
18. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 2189-93.
19. Cuzick J, Terry G, Ho L, et al. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994; 69: 167-71.
20. Mansell ME, Ho L, Terry G, et al. Semi-quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality. Br J Obstet Gynaecol 1994; 101: 807-9.
21. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999; 37: 1030-4.
22. Lo KW, Yeung SW, Cheung TH, et al. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: A study in Chinese population. J Clin Virol 2005; 34: 76-80.
23. Lorincz A. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens. Papillomavirus Rep 1998; 7: 1-5.
24. Onan MA, Taskiran C, Bozdayi G, et al. Assessment of human papilloma viral load of archival cervical intraepithelial neoplasia by real-time polymerase chain reaction in a Turkish population. Eur J Gynaecol Oncol 2005; 26: 632-5.
25. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71.
26. Tsai HT, Wu CH, Lai HL, et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2544-9.
27. Fontaine J, Gravitt P, Duh LM, et al. High level of correlation of human papillomavirus-16 DNA viral load estimates generated by three real-time PCR assays applied on genital specimens. Cancer Epidemiol Biomarkers Prev 2005; 14: 2200-7.
28. Altekruse SF, Lacey JV, Brinton LA, et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol 2003; 188: 657-63.
29. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer 2006; 94: 171-5.
30. Ryu KS, Lee YS, Kim BK, et al. Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers. Exp Mol Med 2001; 33: 136-44.
31. Konya J, Dillner J. Immunity to oncogenic human papillo-maviruses. Adv Cancer Res 2001; 82: 205-38.
32. Sheu BC, Chiou SH, Chang WC, et al. Integration of highrisk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin Immunol 2005; 115: 295-301.
33. Ritz U, Momburg F, Pilch H, et al. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19: 1211-20.
34. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 2006; 118: 129-38.
35. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-40.
36. Brady CS, Bartholomew JS, Burt DJ, et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000; 5: 401-11.
37. Li J, Liu BY, zur Hausen H, et al. Investigation of human papillomavirus (HPV) infection in cervical carcinoma tissues of Chinese women. Chinese J Exp Clin Virol 1996; 10: 50-5.
38. Ma CL, Li YJ, Zhang FC, et al. Detection of HPV16 E6 gene in cervical tissues by quantitative polymerase chain reaction. Natl Med J China 2004; 84: 469-73.